LEXINGTON, Mass., Oct. 5, 2017 /PRNewswire/ -- Aldeyra
Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn
errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced it will present novel data on
the efficacy of ADX-102 in a model of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD) at the 2017 American Society of
Human Genetics Annual Meeting, to be held on October 17 - 21 in Orlando,
Florida.
The abstract summarizing the data was ranked within the top 10% of submissions, and was designated a Reviewers' Choice
Abstract.
SSADHD is a rare inborn error of aldehyde metabolism caused by elevations of succinic semialdehyde, a toxic aldehyde that can
lead to severe neurological disability. By trapping succinic semialdehyde, ADX-102 represents a potential novel approach
for the treatment of SSADHD.
Details of the presentation are as follows:
|
Title:
|
The novel aldehyde trap ADX-102 reduces accumulations of GHB and GABA in
brain tissue from succinic semialdehyde dehydrogenase-deficient mice.
|
|
|
|
Presenter:
|
Susan Macdonald, Ph.D., Vice President of Research and Development at
Aldeyra Therapeutics
|
|
|
|
Date:
|
Thursday, October 19, 2017 at 2:00PM ET – Orange County Convention
Center
|
About Succinic Semialdehyde Dehydrogenase Deficiency
Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD) is a neurological disease caused by genetic mutations that result in
elevated levels of succinic semialdehyde, a toxic aldehyde that can cause severe neurological disease, including motor planning
dysfunction, seizures, speech impairment, intellectual disability, and autism. There is currently no FDA-approved therapy
for SSADHD.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and
commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of
pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development as
topical eye drops for the treatment of ocular inflammation. ADX-102 has now been tested in over 250 patients in Phase 2 clinical
trials in dry eye disease, allergic conjunctivitis, and noninfectious anterior uveitis. A dermatologic form of ADX-102 is in
late-stage clinical development for the treatment of ichthyosis due to Sjögren-Larsson Syndrome, an inborn error of aldehyde
metabolism. ADX-102 has not been approved for sale in the U.S. or elsewhere.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995, including statements regarding Aldeyra's plans and expectations for the development of ADX-102 and the timing thereof; and
the potential of ADX-102 as an agent for the treatment of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD). Aldeyra
intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in
Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you
can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can,"
"would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "aim," "plan" or
the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking
statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.
Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. Important
factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements
include, among others, the timing of enrollment, commencement and completion of Aldeyra's clinical trials, the timing and success
of preclinical studies and clinical trials conducted by Aldeyra and its development partners; updated or refined data based on
Aldeyra's continuing review and quality control analysis of clinical data, Aldeyra's ability to design clinical trials with
protocols and endpoints acceptable to applicable regulatory authorities, the ability to obtain and maintain regulatory approval
to conduct clinical trials and to commercialize Aldeyra's product candidates, and the labeling for any approved products; the
scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates; the size and growth of the
potential markets for Aldeyra's product candidates and the ability to serve those markets; Aldeyra's expectations regarding
Aldeyra's expenses and revenue, the sufficiency of Aldeyra's cash resources and needs for additional financing; the rate and
degree of market acceptance of any of Aldeyra's product candidates; Aldeyra's expectations regarding competition; Aldeyra's
anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra's ability to establish and maintain
development partnerships; Aldeyra's expectations regarding federal, state and foreign regulatory requirements; regulatory
developments in the United States and foreign countries; Aldeyra's ability to obtain and maintain intellectual property
protection for its product candidates; the anticipated trends and challenges in Aldeyra's business and the market in which it
operates; and other factors that are described in the "Risk Factors " and "Management's Discussion and Analysis of Financial
Condition and Results of Operations " sections of Aldeyra's Annual Report on Form 10-K for the year ended December 31,
2016 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, which are on file with the Securities
and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov. Additional factors may be described in those sections of Aldeyra's Quarterly Report on Form 10-Q
for the quarter ended September 30, 2017, to be filed with the SEC in the fourth quarter of 2017.
All of Aldeyra's development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical
and clinical results, and other factors that could delay the initiation or completion of clinical trials.
In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable
factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed and actual results may differ
materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra
undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future
events, or otherwise, except as required by law.
Corporate Contact:
Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 ext. 205
stulipano@aldeyra.com
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Chris.brinzey@westwicke.com
Media Contact:
Cammy Duong
MacDougall Biomedical Communications
781-591-3443
cduong@macbiocom.com
View original content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-announces-presentation-of-novel-data-on-the-efficacy-of-adx-102-in-a-model-of-succinic-semialdehyde-dehydrogenase-activity-at-the-2017-american-society-of-human-genetics-annual-meeting-300531462.html
SOURCE Aldeyra Therapeutics, Inc.